Stephen E. Langabeer

4.3k total citations · 1 hit paper
104 papers, 2.7k citations indexed

About

Stephen E. Langabeer is a scholar working on Genetics, Hematology and Molecular Biology. According to data from OpenAlex, Stephen E. Langabeer has authored 104 papers receiving a total of 2.7k indexed citations (citations by other indexed papers that have themselves been cited), including 70 papers in Genetics, 70 papers in Hematology and 39 papers in Molecular Biology. Recurrent topics in Stephen E. Langabeer's work include Myeloproliferative Neoplasms: Diagnosis and Treatment (48 papers), Acute Myeloid Leukemia Research (42 papers) and Chronic Myeloid Leukemia Treatments (38 papers). Stephen E. Langabeer is often cited by papers focused on Myeloproliferative Neoplasms: Diagnosis and Treatment (48 papers), Acute Myeloid Leukemia Research (42 papers) and Chronic Myeloid Leukemia Treatments (38 papers). Stephen E. Langabeer collaborates with scholars based in Ireland, United Kingdom and United States. Stephen E. Langabeer's co-authors include David C. Linch, Alan K. Burnett, Rosemary E. Gale, Marion E. Frew, David Bowen, Panagiotis Kottaridis, Keith Wheatley, Anthony H. Goldstone, Helen M. Walker and G Harrison and has published in prestigious journals such as SHILAP Revista de lepidopterología, Blood and British Journal of Haematology.

In The Last Decade

Stephen E. Langabeer

94 papers receiving 2.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials

2001 1.2k citations Panagiotis Kottaridis, Marion E. Frew et al. Blood profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Stephen E. Langabeer Ireland	20	2.3k	1.3k	959	584	251	104	2.7k
Carlo Finelli Italy	28	3.2k 1.4×	1.7k 1.4×	1.7k 1.8×	434 0.7×	315 1.3×	108	4.1k
Giovanna Rege‐Cambrin Italy	21	1.4k 0.6×	612 0.5×	893 0.9×	669 1.1×	293 1.2×	70	2.0k
Itsuro Jinnai Japan	20	1.9k 0.8×	621 0.5×	647 0.7×	729 1.2×	277 1.1×	79	2.3k
Brenton G. Mar United States	16	1.5k 0.7×	982 0.8×	667 0.7×	279 0.5×	260 1.0×	33	2.3k
Toshiko Motoji Japan	26	1.5k 0.7×	915 0.7×	700 0.7×	366 0.6×	578 2.3×	121	2.6k
Ya‐Zhen Qin China	23	1.5k 0.7×	503 0.4×	472 0.5×	639 1.1×	305 1.2×	153	1.9k
Andrew Duncombe United Kingdom	18	1.1k 0.5×	1.2k 1.0×	915 1.0×	187 0.3×	145 0.6×	35	2.0k
Hadrian Szpurka United States	17	1.4k 0.6×	939 0.7×	972 1.0×	128 0.2×	176 0.7×	35	2.0k
Andrea Kündgen Germany	19	2.1k 0.9×	655 0.5×	1.1k 1.1×	351 0.6×	231 0.9×	50	2.4k
Christine Terré France	20	1.6k 0.7×	770 0.6×	579 0.6×	448 0.8×	393 1.6×	59	1.9k

Countries citing papers authored by Stephen E. Langabeer

Since Specialization

Citations

This map shows the geographic impact of Stephen E. Langabeer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stephen E. Langabeer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stephen E. Langabeer more than expected).

Fields of papers citing papers by Stephen E. Langabeer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stephen E. Langabeer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stephen E. Langabeer. The network helps show where Stephen E. Langabeer may publish in the future.

Co-authorship network of co-authors of Stephen E. Langabeer

This figure shows the co-authorship network connecting the top 25 collaborators of Stephen E. Langabeer. A scholar is included among the top collaborators of Stephen E. Langabeer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stephen E. Langabeer. Stephen E. Langabeer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Conneally, Eibhlin, et al.. (2023). Molecular diagnostic criteria of myeloproliferative neoplasms. Expert Review of Molecular Diagnostics. 23(12). 1077–1090. 2 indexed citations

Langabeer, Stephen E.. (2020). Reduction in molecular diagnostics of myeloproliferative neoplasms during the COVID-19 pandemic. Irish Journal of Medical Science (1971 -). 190(1). 27–28. 4 indexed citations

Langabeer, Stephen E., et al.. (2020). Can absolute basophilia distinguish e1a2 BCR-ABL1 chronic myeloid leukemia from chronic myelomonocytic leukemia?. Blood Cells Molecules and Diseases. 87. 102521–102521. 1 indexed citations

Flynn, Catherine, et al.. (2020). Repeat JAK2 V617F testing in patients with suspected essential thrombocythaemia. Journal of Clinical Pathology. 73(11). 772–772. 1 indexed citations

Langabeer, Stephen E., et al.. (2020). Patient-Initiated Discontinuation of Tyrosine Kinase Inhibitor for Chronic Myeloid Leukemia. SHILAP Revista de lepidopterología. 2020. 1–4. 1 indexed citations

Brodie, R.R., Stephen E. Langabeer, John Quinn, Máirín E. McMenamin, & Patrick Hayden. (2019). Sorafenib for relapsed FLT3‐ITD‐positive acute myeloid leukemia postallogeneic stem cell transplantation presenting as leukemia cutis. SHILAP Revista de lepidopterología. 7(12). 2579–2580. 2 indexed citations

Crampe, Mireille, et al.. (2019). Molecular Monitoring in Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia with the Variant e13a3BCR-ABL1Fusion. SHILAP Revista de lepidopterología. 2019. 1–4. 2 indexed citations

Langabeer, Stephen E., David O’Brien, Sarah L. McCarron, et al.. (2019). Hairy Cell Leukemia Masquerading as Pancytopenia in Pregnancy. SHILAP Revista de lepidopterología. 2019. 1–3. 2 indexed citations

Langabeer, Stephen E.. (2018). Reflective molecular testing for myeloproliferative neoplasms in patients with elevated serum vitamin B₁₂. Annals of Clinical Biochemistry International Journal of Laboratory Medicine. 55(6). 717–718. 2 indexed citations

10.

Langabeer, Stephen E., et al.. (2018). Protracted Clonal Trajectory of a JAK2 V617F-Positive Myeloproliferative Neoplasm Developing during Long-Term Remission from Acute Myeloid Leukemia. SHILAP Revista de lepidopterología. 2018. 1–4.

11.

Crampe, Mireille, et al.. (2017). Late Emergence of an Imatinib-Resistant ABL1 Kinase Domain Mutation in a Patient with Chronic Myeloid Leukemia. SHILAP Revista de lepidopterología. 2017. 1–3. 2 indexed citations

12.

Crampe, Mireille, Karl Haslam, Emma M. Groarke, et al.. (2017). Chronic Myeloid Leukemia with an e6a2BCR-ABL1Fusion Transcript: Cooperating Mutations at Blast Crisis and Molecular Monitoring. SHILAP Revista de lepidopterología. 2017. 1–5. 2 indexed citations

13.

Langabeer, Stephen E., et al.. (2017). Targeted next-generation sequencing identifies clinically relevant mutations in patients with chronic neutrophilic leukemia at diagnosis and blast crisis. Clinical & Translational Oncology. 20(3). 420–423. 17 indexed citations

14.

Langabeer, Stephen E., et al.. (2017). Molecular Profiling: A Case ofZBTB16-RARAAcute Promyelocytic Leukemia. SHILAP Revista de lepidopterología. 2017. 1–4. 7 indexed citations

15.

Haslam, Karl & Stephen E. Langabeer. (2016). Monitoring Minimal Residual Disease in the Myeloproliferative Neoplasms: Current Applications and Emerging Approaches. BioMed Research International. 2016. 1–6. 8 indexed citations

16.

Langabeer, Stephen E., et al.. (2001). Changes in the pattern of FLT3 mutations between diagnosis and relapse restricts their potential use as markers of minimal residual disease in patients with acute myeloid leukaemia.. UCL Discovery (University College London). 1 indexed citations

17.

Tischkowitz, Marc, Neil V. Morgan, S V Hodgson, et al.. (2001). Mutation analysis of the Fanconi Anaemia group A, C, E, F and G genes in sporadic acute myeloid leukaemia. Journal of Medical Genetics. 38.

18.

Kottaridis, Panagiotis, Marion E. Frew, G Harrison, et al.. (2000). The presence of a FLT3 mutation in AML adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: Analysis of 854 patients from the MRC AML 10 and 12 trials.. Blood. 96. 7 indexed citations

19.

Grimwade, David, Stephen E. Langabeer, Kathy Howe, et al.. (1998). The role of molecular diagnosis & residual disease monitoring in APL: Results of the MRC ATRA trial. British Journal of Haematology. 101. 103–103. 2 indexed citations

20.

Burnett, Alan K., et al.. (1997). Outcome of acute myeloid leukaemias affecting core binding factor subunits: the UK MRC experience. ORCA Online Research @Cardiff (Cardiff University). 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact